
Standigm[®] Expander 2017 Autumn

Standigm *Expander* discovers new and better indications of your in-house compounds.



References:

- CrystalGenomics, Inc. (cancers, under lead optimization) 2 hit out of 10 compounds
- School of pharmacy Ajou university (Parkinson's disease, under validating animal model) 1 hit out of 7 compounds
- Korea institute of science and technology (autism, under validating animal model)
- CRO for NASH (in-house, cell line and gut-liver on a chip validation finished) 2 hit out of 7 compounds
- Japanese pharmaceutical companies